Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
SALUTENSIN-DEMI is an oral small-molecule tablet approved in 1960 for an unspecified indication under Takeda sponsorship. The mechanism of action and specific indications are not documented in available data.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting small, defensive brand team focused on retention rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Zero linked job postings suggest this mature product generates limited hiring. Career roles would focus on defending market share and managing transition to generic competition rather than growth or innovation.
Worked on SALUTENSIN-DEMI at Takeda? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.